Literature DB >> 21750652

Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Stephanie M Wittig-Blaich1, Lukasz A Kacprzyk, Thorsten Eismann, Melanie Bewerunge-Hudler, Petra Kruse, Eva Winkler, Wolfgang S L Strauss, Raimund Hibst, Rudolf Steiner, Mark Schrader, Daniel Mertens, Holger Sültmann, Rainer Wittig.   

Abstract

The serine-protease hepsin is one of the most prominently overexpressed genes in human prostate carcinoma. Forced expression of the enzyme in mice prostates is associated with matrix degradation, invasive growth, and prostate cancer progression. Conversely, hepsin overexpression in metastatic prostate cancer cell lines was reported to induce cell cycle arrest and reduction of invasive growth in vitro. We used a system for doxycycline (dox)-inducible target gene expression in metastasis-derived PC3 cells to analyze the effects of hepsin in a quantitative manner. Loss of viability and adhesion correlated with hepsin expression levels during anchorage-dependent but not anchorage-independent growth. Full expression of hepsin led to cell death and detachment and was specifically associated with reduced phosphorylation of AKT at Ser(473), which was restored by growth on matrix derived from RWPE1 normal prostatic epithelial cells. In the chorioallantoic membrane xenograft model, hepsin overexpression in PC3 cells reduced the viability of tumors but did not suppress invasive growth. The data presented here provide evidence that elevated levels of hepsin interfere with cell adhesion and viability in the background of prostate cancer as well as other tissue types, the details of which depend on the microenvironment provided. Our findings suggest that overexpression of the enzyme in prostate carcinogenesis must be spatially and temporally restricted for the efficient development of tumors and metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750652      PMCID: PMC3132844          DOI: 10.1593/neo.11294

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  40 in total

1.  Cell adhesion assays.

Authors:  M J Humphries
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  HEPSIN inhibits cell growth/invasion in prostate cancer cells.

Authors:  Vasantha Srikantan; Michael Valladares; Johng S Rhim; Judd W Moul; Shiv Srivastava
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

4.  Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model.

Authors:  K Kunzi-Rapp; F Genze; R Küfer; E Reich; R E Hautmann; J E Gschwend
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

5.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

6.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

7.  Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.

Authors:  Carsten Stephan; George M Yousef; Andreas Scorilas; Klaus Jung; Monika Jung; Glen Kristiansen; Steffen Hauptmann; Tadaaki Kishi; Terukazu Nakamura; Stefan A Loening; Eleftherios P Diamandis
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

Review 8.  Tumour microenvironment: laminin 332 in squamous-cell carcinoma.

Authors:  M Peter Marinkovich
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

9.  Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation.

Authors:  Y Kazama; T Hamamoto; D C Foster; W Kisiel
Journal:  J Biol Chem       Date:  1995-01-06       Impact factor: 5.157

10.  Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells.

Authors:  S Persad; S Attwell; V Gray; M Delcommenne; A Troussard; J Sanghera; S Dedhar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  16 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Authors:  Euan A Stronach; Michelle Chen; Elaina N Maginn; Roshan Agarwal; Gordon B Mills; Harpreet Wasan; Hani Gabra
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

4.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 5.  Cell surface-anchored serine proteases in cancer progression and metastasis.

Authors:  Carly E Martin; Karin List
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

6.  Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.

Authors:  Ho-Jeong Lee; Hyun-Kyung Yu; John N Papadopoulos; Seung Wook Kim; Junqin He; Yong-Keun Park; Yeup Yoon; Jang-Seong Kim; Sun Jin Kim
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

7.  ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.

Authors:  Lukasz A Kacprzyk; Mark Laible; Tatjana Andrasiuk; Jan C Brase; Stefan T Börno; Maria Fälth; Ruprecht Kuner; Hans Lehrach; Michal R Schweiger; Holger Sültmann
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

8.  SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.

Authors:  Filipa Quintela Vieira; Pedro Costa-Pinheiro; Diogo Almeida-Rios; Inês Graça; Sara Monteiro-Reis; Susana Simões-Sousa; Isa Carneiro; Elsa Joana Sousa; Maria Inês Godinho; Fátima Baltazar; Rui Henrique; Carmen Jerónimo
Journal:  Oncotarget       Date:  2015-05-30

9.  Biomarkers in prostate cancer epidemiology.

Authors:  Mukesh Verma; Payal Patel; Mudit Verma
Journal:  Cancers (Basel)       Date:  2011-09-30       Impact factor: 6.639

10.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.